March Trial Set For Patent Battle Over Glaucoma Treatment

Law360, London (February 26, 2021, 6:51 PM GMT) -- A Novartis AG eye-care spinoff is set to battle two generic-drug makers in long-running litigation over the validity of its glaucoma treatment patent at a trial starting in mid-March.

Alcon Research LLC, a subsidiary of Novartis spinoff Alcon, sued Aspire Pharma Ltd. and manufacturer Pharmathen SA in 2014 for threatened infringement of its Travoprost medication patent. The High Court litigation has been consolidated with its 2015 suit against British generics company Actavis UK Ltd., now rebranded as Accord Healthcare.

Travoprost is sold by Novartis under the brand name Travatan. Dispensed by eye drops, it's used to treat high pressure inside the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!